Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
Conclusions: IMbrave150 and GO30140 patients with unresectable HCC had varying baseline hepatic impairment and high enrollment from Asia. PK data demonstrated considerable exposure overlap across groups. Treatment was tolerable across groups. No need for dose adjustment based on mild or moderate hepatic impairment or region is recommended based on this analysis.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 10, 2021 Category: Cancer & Oncology Source Type: research

Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody
Conclusion: The combined score including Wnt/ β-catenin activation, CPS of PD-L1, and degree of CD8+ TILs in HCC is informative for predicting the response to ICI in HCC cases. Constitutive activation of β-catenin can induce an immune cold phenotype with downregulation of immune-related genes, and immunohistochemistry-based evaluation is beneficial for identifying the subgroup that shows a good response to ICI.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 9, 2021 Category: Cancer & Oncology Source Type: research

APPLE News
Liver Cancer 2021;10:287 –288 (Source: Liver Cancer)
Source: Liver Cancer - June 8, 2021 Category: Cancer & Oncology Source Type: research

Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals
Conclusions: Obesity and heavy alcohol consumption increased the risk of HCC development after SVR.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 4, 2021 Category: Cancer & Oncology Source Type: research

Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 1, 2021 Category: Cancer & Oncology Source Type: research

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort
Conclusion: Cabozantinib treatment was effective, safe, and feasible in patients with advanced HCC in patients with compensated cirrhosis. Patients in the real-life setting had more advanced liver disease – in which 25% of patients were Child-Pugh B. However, OS in patients with Child-Pugh A cirrhosis was similar to that reported in the phase 3 trial (CELESTIAL).Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 1, 2021 Category: Cancer & Oncology Source Type: research

Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - May 25, 2021 Category: Cancer & Oncology Source Type: research

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a...
Source: Liver Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: research

Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
Conclusions: CD8 T-cell exhaustion in tumor microenvironment may predict better efficacy of ICI therapy for HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - May 12, 2021 Category: Cancer & Oncology Source Type: research

Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma
Conclusion: NFD has been identified as an important novel prognostic biomarker in pCCA patients. NFD alone and in combination with nodal status in particular allows to stratify pCCA patients based on their risk for inferior oncological outcomes after curative-intent surgery.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - May 6, 2021 Category: Cancer & Oncology Source Type: research

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis
Background: Most phase 3 clinical trials of systemic therapy for first-line unresectable hepatocellular carcinoma (HCC) have failed, with the exception of SHARP, REFLECT, and IMbrave150. We conducted indirect comparisons of therapies evaluated for first-line HCC treatment.Summary: We conducted a systematic review and meta-analysis of treatments for adults with locally advanced or metastatic unresectable HCC and no prior systemic treatment, including atezolizu ­mab plus bevacizumab, sorafenib, lenvatinib, nivolumab, selective internal radiotherapy (SIRT), transarterial chemoembolization, and placebo or best supportive care...
Source: Liver Cancer - May 6, 2021 Category: Cancer & Oncology Source Type: research

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial
Conclusion: Pembrolizumab demonstrated antitumor activity and was well tolerated in the Asian subgroup of KEYNOTE-240. A trend toward greater benefit with pembrolizumab in the Asian subgroup was observed compared with the overall cohort, supporting further evaluation of pembrolizumab treatment in this population.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 27, 2021 Category: Cancer & Oncology Source Type: research

Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis
Conclusion: HCC patients with vascular invasion may benefit from surgical resection compared to systemic therapies. Demographic and clinical features of HCC patients and region and type of treating facility were associated with surgical resection versus systemic treatment.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 23, 2021 Category: Cancer & Oncology Source Type: research

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
Conclusion: Clinically meaningful improvements in OS and PFS observed with atezolizumab plus bevacizumab versus sorafenib suggest that atezolizumab plus bevacizumab may become a practice-changing treatment for Chinese patients with unresectable HCC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 23, 2021 Category: Cancer & Oncology Source Type: research

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Conclusion: Sorafenib may not be a candidate for use as a posttreatment agent after lenvatinib, according to the results of the present study. Regorafenib has the potential to become an appropriate posttreatment agent after lenvatinib.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 20, 2021 Category: Cancer & Oncology Source Type: research